US Patent 10,517,882: Claim Scope, Minocycline Foam Coverage, and Patent Landscape

US Patent 10,517,882 protects a narrow method of treating an infected acne lesion without scarring using a surfactant-free minocycline foam. The patent does not broadly claim every topical minocycline product. Infringement requires use of a foam made from a composition containing specified oil, wax, fatty alcohol, fatty acid, and minocycline ranges, together with the claimed acne-treatment regimen.

The patent is commercially relevant to Amzeeq, a 4% minocycline topical foam approved by the FDA for inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adults and pediatric patients aged 9 years and older (FDA, 2019).

What does US Patent 10,517,882 protect?

The patent’s independent claim protects a treatment method with four principal components:

A patient has an infected acne lesion.
A minocycline antibiotic foam is applied topically at least once daily.
The treatment is directed to healing the lesion without scarring.
The foam is generated from a propellant-based composition with a defined anhydrous or substantially oil-based formulation.

The formulation must contain:

Required component	Claimed limitation
Hydrophobic oil	60% to 90% by weight
Permitted oils	Mineral oil, soybean oil, coconut oil, cyclomethicone, or mixtures
Wax	Beeswax, hydrogenated castor oil, or mixtures
Solid fatty alcohol	C14-C22 carbon chain
Solid fatty acid	C12-C28 carbon chain
Minocycline	0.2% to 10% by weight
Surfactant	Excluded
Propellant	Liquefied or compressed gas added to produce foam
Administration	Topical and at least once daily
Indication	Infected acne lesion
Treatment objective	Healing without scarring

The claim is therefore a combination claim. A product or method that satisfies only the minocycline and foam limitations, but lacks the required oil system or contains a surfactant, may fall outside claim 1.

How narrow is claim 1 of US 10,517,882?

Claim 1 is materially narrower than a general claim to topical minocycline foam.

The claim requires the foamable composition to include all of the following:

A high concentration of specified hydrophobic oils.
A listed wax.
A solid fatty alcohol in the C14-C22 range.
A solid fatty acid in the C12-C28 range.
Minocycline at 0.2% to 10% by weight.
No surfactant.

The absence of a surfactant is a significant limitation. Many pharmaceutical foams rely on surfactants, emulsifiers, or solubilizers to stabilize the formulation and improve spreading. A competing minocycline foam using a surfactant could avoid literal infringement of claim 1, subject to any doctrine-of-equivalents analysis.

The claim also requires a propellant-generated foam. A cream, gel, lotion, solution, aerosolized spray, or non-foaming emulsion would not literally satisfy the foam limitation.

What do claims 2 through 8 add?

The dependent claims create narrower fallback positions around the composition and treatment method.

Claim	Added limitation	Practical significance
2	Minocycline may be free base, salt, hydrate, or complex	Broadens the chemical form covered within the claimed formulation
3	Minocycline is 1% to 4% by weight	Directly captures commercially relevant concentrations, including a 4% product
4	Fatty alcohol is myristyl, cetostearyl, stearyl, behenyl alcohol, or mixture	Narrows the fatty-alcohol component to common formulation excipients
5	Fatty acid includes stearic acid	Protects a conventional fatty-acid implementation
6	Fumed silica may be included	Covers a formulation using silica for rheology, structure, or foam properties
7	Minocycline is micronized	Addresses particle-size engineering and dispersion
8	An additional active agent may be included	Extends coverage to combination treatments

Claim 3 is commercially important because it includes a 1% to 4% range. A 4% minocycline foam falls at the upper endpoint of that claim. Claim 7 can complicate design-around efforts when micronized minocycline is used to improve uniformity or topical delivery.

Does US 10,517,882 claim Amzeeq?

US 10,517,882 appears directed to the formulation and use characteristics associated with minocycline foam products such as Amzeeq. Amzeeq contains 4% minocycline and is supplied as a topical foam. The FDA-approved product is indicated for inflammatory lesions of moderate-to-severe acne vulgaris, not exclusively for an “infected acne lesion” or an explicit “without scarring” indication (FDA, 2019).

That distinction matters. Patent infringement is assessed against the product and the accused acts, not solely against the FDA label. A method claim can be infringed through physician or patient use even where the FDA label does not repeat every phrase in the patent claim. The “without scarring” language may be treated as a treatment objective, result, or limiting intended-use element depending on claim construction and the evidence developed in litigation.

A product-level infringement analysis would need to establish:

The actual formulation composition.
The presence and concentration of each claimed excipient.
The absence of surfactant.
The use of a liquefied or compressed gas propellant.
The dosing frequency.
Whether the use is directed to an infected acne lesion.
Whether the claimed no-scarring limitation is met.

What is the FDA regulatory status of minocycline foam?

Amzeeq was approved by the FDA in October 2019 under NDA 213055. It is a topical foam containing 4% minocycline hydrochloride. The approved product is used once daily for moderate-to-severe acne vulgaris (FDA, 2019).

Regulatory item	Status
Product	Amzeeq
Active ingredient	Minocycline
Dosage form	Topical foam
Strength	4%
NDA	213055
FDA approval	October 2019
Approved use	Inflammatory lesions of moderate-to-severe acne vulgaris
Regulatory pathway	New drug application
Biosimilar pathway	Not applicable

Minocycline is a small-molecule tetracycline antibiotic. Biosimilar rules under section 351(k) of the Public Health Service Act do not apply. A competing manufacturer would generally pursue an abbreviated new drug application, a section 505(b)(2) application, or a full NDA, depending on the product and reference-product strategy.

What patents protect minocycline foam products?

The patent estate around minocycline foam products generally falls into four categories:

Formulation patents

These patents cover the oil-based foam matrix, waxes, fatty alcohols, fatty acids, particle engineering, propellant systems, and physical stability. US 10,517,882 is primarily relevant to this category, although its granted claims are drafted as treatment-method claims rather than as a standalone composition claim.

Formulation patents can create meaningful barriers because an ANDA applicant may need to disclose its inactive ingredients and manufacturing process. A product that copies the commercial formulation may face both product and method-of-use theories. A materially different vehicle may avoid a formulation claim but lose equivalence in spreadability, stability, drug release, or patient usability.

Method-of-use patents

US 10,517,882 is a method-of-use patent with formulation limitations. It requires topical administration at least once daily to an infected acne lesion and ties the treatment to healing without scarring.

This structure can be stronger than a pure indication claim in some respects because it links the clinical use to a particular formulation. It can also be easier to design around if a competitor changes the formulation, dosing instructions, or therapeutic positioning.

Concentration and particle-size claims

Claims directed to 1% to 4% minocycline and micronized minocycline can cover commercially practical development choices. These limitations may be important in ANDA litigation because a generic applicant could attempt to use a different concentration, particle-size distribution, or chemical form.

Manufacturing and process claims

Manufacturing protection may cover preparation of the oil phase, dispersion of minocycline, propellant filling, foam formation, and control of particle size. Process claims can increase development costs even when a competitor avoids direct infringement of the marketed-product claims. They are less likely to create an independent barrier if the accused manufacturer operates outside the United States, unless imported products are made by a patented process covered by 35 U.S.C. § 271(g).

How strong is the patent estate for US 10,517,882?

The patent has moderate claim breadth and potentially strong commercial relevance.

Strengths

Claim 1 captures the core combination of topical minocycline foam and a specific oil-based, surfactant-free vehicle.
Claim 3 reaches the commercially important 1% to 4% concentration range.
Claim 7 addresses micronized minocycline, a common approach for improving topical dispersion.
The claim includes multiple excipient classes, making it difficult to avoid all formulation limitations while retaining the same vehicle architecture.
A method claim may be asserted against use instructions, prescribing practices, or product labeling.

Vulnerabilities

Every limitation of claim 1 must be met.
The claim requires a particular composition, not merely any minocycline foam.
The surfactant exclusion creates a clear design-around path.
A product with a different oil system, wax, fatty alcohol, or fatty acid may avoid literal infringement.
The “infected acne lesion” and “without scarring” language may generate claim-construction disputes.
Prior-art references involving tetracycline foams, oil-based dermatological foams, or surfactant-free aerosol compositions could affect validity under sections 102 and 103.
The claim’s result-oriented language may be challenged as indefinite or insufficiently supported, depending on the specification and prosecution history.

Patent strength depends on the complete intrinsic record, including the specification, prosecution history, cited references, terminal disclaimers, patent-term adjustment, and related continuation applications. The claim text alone does not establish the enforceability of every family member.

When does US Patent 10,517,882 lose exclusivity?

US Patent 10,517,882 was granted on December 31, 2019. Its nominal patent term is generally calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.

The grant date does not determine the expiration date. For a reliable expiration analysis, the controlling data are:

Earliest priority and nonprovisional filing dates.
Patent-term adjustment listed by the USPTO.
Any terminal disclaimer.
Patent-term extension under 35 U.S.C. § 156.
Patent-term restoration or pediatric exclusivity.
Continuation and divisional relationships.

The patent should not be treated as expiring 20 years after issuance. The statutory term is normally measured from the relevant filing date, not the grant date (USPTO, n.d.-a).

What is the Orange Book status of the minocycline foam patents?

FDA Orange Book listings are product-specific. A patent is relevant to an ANDA only if it is listed for the applicable reference product and dosage form. Orange Book-listed patents may include formulation, method-of-use, or other patent categories, but listing does not itself establish validity or infringement (FDA, n.d.-a).

For Amzeeq, an Orange Book review should compare:

Review item	Business implication
Listed patent number	Determines patent certifications required in an ANDA
Patent use code	Identifies the protected indication
Expiration date	Establishes the listed exclusivity endpoint
Delisting status	May alter Paragraph IV exposure
NDA supplement history	May affect labeling and use-code scope
Pediatric exclusivity	Can add six months to qualifying listed patents

US 10,517,882 should be evaluated against the current Orange Book entry for NDA 213055 rather than assumed to be listed solely because it concerns minocycline foam.

Which companies could challenge the patent?

Potential challengers include generic manufacturers with topical dermatology portfolios, contract development organizations supporting ANDA sponsors, and companies developing alternative minocycline vehicles. The most credible challenger would likely pursue one of three strategies:

Use a non-foaming topical formulation.
Use a foam containing a surfactant or a different oil system.
Use a different minocycline concentration, chemical form, particle-size distribution, or dosing regimen.

An ANDA applicant seeking approval before the expiration of a listed patent may submit a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger a patent-infringement action and a statutory stay of FDA approval for up to 30 months under the Hatch-Waxman framework (FDA, n.d.-b).

No Paragraph IV litigation outcome can be inferred from the patent claims alone. Litigation status must be verified through federal court records and the FDA Orange Book.

What generic launch scenarios exist?

Early settlement launch

A challenger could obtain a licensed or covenant-based entry date before patent expiration. The terms may include a launch date, royalty, restricted supply arrangement, or settlement of patent claims.

At-risk launch

A company may launch before final resolution after receiving a favorable noninfringement or invalidity position. This exposes the company to damages, injunction risk, and possible loss of market access.

Formulation workaround

A competitor could avoid the patent by using a non-covered vehicle. This may reduce litigation risk but create regulatory, manufacturing, or clinical-development costs.

Post-expiration launch

A conventional ANDA launch after the relevant patent and regulatory exclusivity periods is the lowest litigation-risk scenario, but it may occur after branded market share and prescriber loyalty have been established.

How does the patent compare with competing acne products?

Product category	Active ingredient	Dosage form	Primary IP risk
Amzeeq	Minocycline 4%	Topical foam	Foam formulation and method claims
Zilxi	Minocycline 1.5%	Topical foam	Separate product, formulation, and use patent estate
Generic oral minocycline	Minocycline	Capsule or tablet	Oral-product patents generally differ from foam patents
Topical clindamycin	Clindamycin	Gel, lotion, solution, foam	Different active ingredient and formulation estate
Topical retinoids	Tretinoin, adapalene, trifarotene	Cream, gel, lotion	Retinoid formulation and use patents
Benzoyl peroxide products	Benzoyl peroxide	Gel, wash, foam	Different active and vehicle technology

Zilxi is a direct dosage-form competitor but is not automatically covered by US 10,517,882. Its 1.5% minocycline concentration may fall within claim 3, but infringement would still require the claimed oil, wax, fatty alcohol, fatty acid, propellant, surfactant exclusion, and method-of-use elements.

What manufacturing and IP barriers affect competitors?

The main technical barriers are formulation stability, uniform minocycline dispersion, foam quality, propellant compatibility, dose reproducibility, and control of oxidation or degradation in the oil phase. A substitute formulation may avoid literal infringement but require new stability studies, comparative characterization, and potentially clinical bridging.

The patent’s no-surfactant limitation also creates a technical tradeoff. Removing surfactants can reduce irritation or simplify the excipient profile, but it may increase demands on wax selection, fatty alcohol structure, silica content, particle size, and propellant processing.

Geographically, US 10,517,882 has no direct effect outside the United States. Foreign counterparts must be analyzed separately by jurisdiction. Parallel rights in Europe, Canada, Japan, or other markets may have different claim scope, prosecution histories, oppositions, and expiration dates.

Key Takeaways

US 10,517,882 is a narrow combination method patent, not a broad patent on all topical minocycline products.
The independent claim requires a propellant-generated, surfactant-free foam with specified oil, wax, fatty alcohol, fatty acid, and minocycline components.
Claim 3 is commercially significant because it covers minocycline concentrations from 1% through 4%.
Claims 6 and 7 add fumed silica and micronized minocycline coverage.
Amzeeq is a relevant commercial product because it is a 4% minocycline topical foam approved under NDA 213055.
A generic can potentially design around the patent through a different vehicle, surfactant system, concentration, dosing regimen, or non-foaming dosage form.
Orange Book listing, patent-term adjustment, terminal disclaimers, related patents, and Paragraph IV activity must be evaluated separately from the granted claim text.
Biosimilar analysis is not applicable because minocycline is a small molecule.
The strongest commercial risk is a competing topical foam that reproduces the claimed surfactant-free oil-based architecture.
The principal validity and enforcement issues are claim construction, prior art, written description, indefiniteness, and proof that the accused product satisfies every formulation limitation.

FAQs About US Patent 10,517,882 and Minocycline Foam

Does US 10,517,882 cover oral minocycline?

No. The claims require topical administration of a minocycline antibiotic foam. Oral capsules, tablets, and other systemic dosage forms do not satisfy the claimed topical foam limitations.

Does a minocycline foam with surfactant infringe claim 1?

It would not literally satisfy the express requirement that the foamable composition does not comprise a surfactant. The patent owner could still evaluate an equivalence theory, but literal infringement would be substantially more difficult.

Does the patent cover a 4% minocycline foam?

Yes, claim 3 expressly covers a composition containing 1% to 4% minocycline, assuming all limitations of claim 1 are also met.

Can a generic avoid the patent by using minocycline hydrochloride instead of free-base minocycline?

Not necessarily. Claim 2 expressly covers free base, salt, hydrate, and complex forms. Minocycline hydrochloride would require analysis under the salt-form limitation and the remaining claims.

Is Zilxi automatically blocked by US 10,517,882?

No. Zilxi’s 1.5% minocycline strength may fall within one numerical range, but infringement would depend on its complete formulation, propellant system, surfactant content, administration instructions, and the interpretation of the acne-lesion limitations.

References

Food and Drug Administration. (2019). Amzeeq (minocycline) topical foam, 4%: Prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.

Food and Drug Administration. (n.d.-b). Paragraph IV patent certifications and 30-month stays under the Hatch-Waxman Amendments. U.S. Department of Health and Human Services.

United States Patent and Trademark Office. (n.d.-a). Patent term adjustment. U.S. Department of Commerce.

United States Patent and Trademark Office. (2019). U.S. Patent No. 10,517,882: Methods for healing infected acne lesions without scarring. U.S. Department of Commerce.

United States Congress. (2012). Leahy-Smith America Invents Act and amendments to title 35 of the United States Code. 35 U.S.C. §§ 102, 103, 271, 156.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	AMZEEQ	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	212379-001	Oct 18, 2019		RX	Yes	Yes	10,517,882	⤷ Start Trial				TREATMENT OF NON-NODULAR ACNE VULGARIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010302350	⤷ Start Trial
Australia	2015224534	⤷ Start Trial
Brazil	112012007473	⤷ Start Trial
Canada	2776366	⤷ Start Trial
Canada	2776471	⤷ Start Trial
Canada	2776474	⤷ Start Trial
Canada	2776482	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,517,882

Which drugs does patent 10,517,882 protect, and when does it expire?

Summary for Patent: 10,517,882